Related Experiment Videos
High-dose continuous-infusion fosfestrol in hormone-resistant prostate cancer
Background:
The initial treatment of advanced-stage prostate cancer is total androgen deprivation. Autonomous proliferation of primarily or secondarily hormonal unresponsive cells may explain the development of hormone-refractory status. The median survival of patients with hormone-resistant disease is short; there is no standard regimen of chemotherapy.
Methods:
Fosfestrol or diethylstilbestrol diphosphate and its metabolites have cytotoxic activity in hormone-refractory prostatic cell lines. Pharmacokinetic studies have shown that fosfestrol metabolites have a short half-life that supports the use of long-term infusion in the clinic.
Results:
A review of the literature shows that high-dose fosfestrol induces no objective response, a greater than 50% tumor marker decrease in 50% of patients, a subjective improvement in 75% of patients, and cardiovascular complications in 5% of patients. The median survival time of patients is 5 months after the onset of treatment.
Conclusions:
An exact evaluation of the role of high-dose estrogens requires additional investigation.
Insights
High-dose fosfestrol shows potential in treating advanced prostate cancer, offering symptom relief and tumor marker reduction in many patients. However, further research is needed to confirm its exact role and efficacy.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced prostate cancer is initially treated with androgen deprivation therapy.
- Hormone-refractory prostate cancer develops from autonomous cell proliferation.
- Patients with hormone-resistant prostate cancer have a short median survival and lack standard chemotherapy.
Purpose of the Study:
- To evaluate the efficacy and safety of high-dose fosfestrol in hormone-refractory prostate cancer.
- To review existing literature on fosfestrol treatment for advanced prostate cancer.
Main Methods:
- Literature review of studies using high-dose fosfestrol (diethylstilbestrol diphosphate).
- Analysis of pharmacokinetic data for fosfestrol metabolites.
- Assessment of objective response, tumor marker decrease, subjective improvement, and complications.
Main Results:
- High-dose fosfestrol did not induce objective responses.
- A 50% tumor marker decrease was observed in 50% of patients.
- 75% of patients reported subjective improvement, with 5% experiencing cardiovascular complications.
- Median survival was 5 months.
Conclusions:
- High-dose estrogens, specifically fosfestrol, may offer palliative benefits in hormone-refractory prostate cancer.
- Further investigation is required to precisely define the role of high-dose estrogens in this patient population.